Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial
- Citation:
- Lancet Oncol vol 14 (13) 1317-1325
- Year:
- 2013
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Received
- Note:
- Pharmas:
- Grants:
- CA33601, U10 CA76001, U10 CA031946, U10 CA033601, P30 CA015083, U10 CA076001, CA31946
- Corr. Author:
- Authors:
- Aman U Buzdar Vera J Suman Funda Meric-Bernstam A Marilyn Leitch Matthew J Ellis Judy C Boughey Gary Unzeitig Melanie Royce Linda M McCall Michael S Ewer Kelly K Hunt
- Networks:
- Study
- ACOSOG-Z1041
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Article